Biorelevant in vitro performance testing of orally administered dosage forms-workshop report

Area of Science:

• Pharmaceutical Sciences
• Drug Delivery
• Biopharmaceutics

Background:

• Biorelevant in vitro performance testing is crucial for assessing oral dosage form behavior in vivo.
• These tests simulate intraluminal conditions to predict drug product performance.
• Biorelevant tests aim to reduce reliance on in vivo studies and mitigate risks in bioequivalence assessments.

Framework:

• The report reviews current in vitro performance tests for their ability to predict in vivo drug product performance.
• It examines the generation of successful in vitro-in vivo correlations (IVIVCs) for oral dosage forms.
• Efforts to enhance the predictive power of biorelevant tests are summarized.

Implementation:

• The content is based on presentations from a 2013 workshop on biorelevant in vitro performance testing.
• It incorporates insights from a 2012 symposium on the same topic.
• Key organizations involved include the FIP Dissolution/Drug Release Focus Group and the American Association of Pharmaceutical Scientists (AAPS).

Implications:

• Improved biorelevant testing can lead to more efficient drug development pipelines.
• Enhanced in vitro-in vivo correlations can reduce the cost and time of bioequivalence studies.
• This approach supports the development of more predictable and effective oral drug products.